Agilent Technologies, Inc. $A Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 10.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,000 shares of the medical research company’s stock after selling 5,000 shares during the quarter. Agilent Technologies makes up 1.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 20th biggest position. Sivik Global Healthcare LLC’s holdings in Agilent Technologies were worth $5,310,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of A. Generation Investment Management LLP lifted its stake in shares of Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after acquiring an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after acquiring an additional 604,124 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock worth $109,481,000 after acquiring an additional 548,344 shares in the last quarter. Woodline Partners LP lifted its stake in shares of Agilent Technologies by 681.6% in the first quarter. Woodline Partners LP now owns 522,073 shares of the medical research company’s stock worth $61,072,000 after acquiring an additional 455,276 shares in the last quarter. Finally, Parnassus Investments LLC raised its stake in Agilent Technologies by 38.3% during the first quarter. Parnassus Investments LLC now owns 1,577,999 shares of the medical research company’s stock valued at $184,594,000 after buying an additional 437,242 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have recently commented on A. Rothschild Redb upgraded Agilent Technologies to a “strong-buy” rating in a research report on Wednesday. Barclays lifted their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. JPMorgan Chase & Co. increased their target price on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday. Robert W. Baird lifted their price target on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $148.69.

Agilent Technologies Stock Down 2.5%

Agilent Technologies stock opened at $136.62 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company has a 50-day simple moving average of $125.04 and a 200-day simple moving average of $117.03. The firm has a market capitalization of $38.73 billion, a P/E ratio of 32.07, a P/E/G ratio of 4.46 and a beta of 1.26.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the previous year, the business posted $1.32 EPS. Agilent Technologies’s revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be paid a $0.248 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.